Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Development and Validation of Staging Systems for AA Amyloidosis.
J Am Soc Nephrol. 2024 Jun 1;35(6):782-794. doi: 10.1681/ASN.0000000000000339. Epub 2024 Mar 21.
J Am Soc Nephrol. 2024.
PMID: 38512269
No abstract available.
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators.
Maurer MS, et al.
N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757.
N Engl J Med. 2023.
PMID: 37888916
Free PMC article.
Clinical Trial.
Item in Clipboard
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients.
Basset M, Milani P, Ferretti VV, Nuvolone M, Foli A, Benigna F, Nanci M, Bozzola M, Ripepi J, Sesta M, Russo F, Bosoni T, Klersy C, Albertini R, Merlini G, Palladini G.
Basset M, et al. Among authors: benigna f.
Clin Chem Lab Med. 2022 Jan 13;60(3):386-393. doi: 10.1515/cclm-2021-0912. Print 2022 Feb 23.
Clin Chem Lab Med. 2022.
PMID: 35018751
Free article.
Item in Clipboard
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.
Basset M, Milani P, Nuvolone M, Benigna F, Rodigari L, Foli A, Merlini G, Palladini G.
Basset M, et al. Among authors: benigna f.
Blood Adv. 2020 Sep 8;4(17):4175-4179. doi: 10.1182/bloodadvances.2020002219.
Blood Adv. 2020.
PMID: 32886751
Free PMC article.
Item in Clipboard
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.
Milani P, Basset M, Nuvolone M, Benigna F, Rodigari L, Lavatelli F, Foli A, Merlini G, Palladini G.
Milani P, et al. Among authors: benigna f.
Blood Cancer J. 2020 Sep 1;10(8):90. doi: 10.1038/s41408-020-00355-6.
Blood Cancer J. 2020.
PMID: 32873771
Free PMC article.
Item in Clipboard
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
Milani P, Fazio F, Basset M, Berno T, Larocca A, Foli A, Riva M, Benigna F, Oliva S, Nuvolone M, Rodigari L, Petrucci MT, Merlini G, Palladini G.
Milani P, et al. Among authors: benigna f.
Am J Hematol. 2020 Aug;95(8):900-905. doi: 10.1002/ajh.25828. Epub 2020 Apr 30.
Am J Hematol. 2020.
PMID: 32282971
Free article.
Item in Clipboard
Cite
Cite